Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Dia Roy, Cassandra Gilmour, Sachin Patnaik, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21

Showing 21 citing articles:

Parps in immune response: Potential targets for cancer immunotherapy
S Wang, Jingling Huang, T. X. Zeng, et al.
Biochemical Pharmacology (2025) Vol. 234, pp. 116803-116803
Closed Access | Times Cited: 2
LRIG1 engages ligand VISTA and impairs tumor-specific CD8 + T cell responses
Hieu Minh Ta, Dia Roy, Keman Zhang, et al.
Science Immunology (2024) Vol. 9, Iss. 95
Open Access | Times Cited: 14
Cutting-Edge Therapies for Lung Cancer
Anita Silas La’ah, Shih‐Hwa Chiou
Cells (2024) Vol. 13, Iss. 5, pp. 436-436
Open Access | Times Cited: 9
Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications
Mingjian Piao, Nan Zhang, Jiongyuan Li, et al.
International Immunopharmacology (2025) Vol. 147, pp. 114052-114052
Open Access | Times Cited: 1
Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer
Xianqiang Liu, Xiaowei Xi, Shengshan Xu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Introductory Chapter: The Enigma of Hepatitis B Therapeutics
Mark A. Feitelson
IntechOpen eBooks (2025)
Closed Access
Enhanced co-expression of TIGIT and PD-1 on γδ T cells correlates with clinical features and laboratory parameters in patients with primary Sjögren’s syndrome
Saizhe Song, Yanhong Yang, Tian Ren, et al.
Clinical Rheumatology (2025)
Closed Access
Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies
Suman Giri, Gopal Lamichhane, Jitendra Pandey, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2923-2923
Open Access
Emerging new immune checkpoint inhibitors in solid tumor immunotherapy
Amirhoushang Poorkhani, Mahboubeh Tajaldini, Farahnazsadat Ahmadi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Tertiary Lymphoid Structures Are Associated with Progression-Free Survival of Peripheral Neuroblastic Tumor Patients
R Rothe, Therés Golle, Basma Hachkar, et al.
Cancers (2025) Vol. 17, Iss. 8, pp. 1303-1303
Open Access
An antibody targeting an immune checkpoint molecule BTN2A2 enhances anti-tumor immunity
Xiao Li, Rong Hu, Wei Chen, et al.
Neoplasia (2025) Vol. 65, pp. 101161-101161
Closed Access
Phytotherapeutics in Cancer: From Potential Drug Candidates to Clinical Translation
Parul Grover, Kulbhushan Thakur, Monika Bhardwaj, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 12, pp. 1050-1074
Closed Access | Times Cited: 3
Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano‐Delivery Systems for Enhanced Immunotherapy
Xin Huang, Weiyue Zhang
Small Methods (2023) Vol. 8, Iss. 8
Closed Access | Times Cited: 8
TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells
Beatrice Claudia Cianciotti, Zulma Magnani, Alessia Ugolini, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection
Gabriela M. Webb, Cleiton Pessoa, Allyson J. McCullen, et al.
Journal of Virology (2024) Vol. 98, Iss. 6
Open Access | Times Cited: 2
Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity
Taylor J. Moon, Hieu Minh Ta, Anubhuti Bhalotia, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 8, pp. e008977-e008977
Open Access | Times Cited: 2
The World of Immunotherapy Needs More Than PD-1/PD-L1—Two of the New Kids on the Block: LAG-3 and TIGIT
João Martins Gama, Paulo Ricardo Teixeira, Rui Caetano Oliveira
Onco (2024) Vol. 4, Iss. 3, pp. 116-130
Open Access | Times Cited: 1
Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms
Biswanath Majumder, Nishanth Belugali Nataraj, Leela Maitreyi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Exploratory Research for HIF-1α Overexpression Tumor Antigen in the Activation of Dendritic Cells and the Potent Anti-Tumor Immune Response
Jinjin Zhao, Haiguang Zhang, Yilin Zhao, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 1813-1822
Open Access | Times Cited: 1
T-Cell Immunoglobulin and Mucin Domain 3 (TIM-3) Gene Expression as a Negative Biomarker of B-Cell Acute Lymphoblastic Leukemia
Fatemah Basingab, Manar Bashanfer, Aisha Alrofaidi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11148-11148
Open Access
The oncogenic role and prognostic value of PXDN in human stomach adenocarcinoma
Yuan Tian, Shenghui Qiu, Yang Song, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
VISTA in hematological malignancies: a review of the literature
Yuanjia Duan, Xiaotong Ren, Xinyu Guo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
The Oncogenic Role and Prognostic Value of PXDN in Human Stomach Adenocarcinoma
Yuan Tian, Shenghui Qiu, Yang Song, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top